NA-Selank Amidate
- Category
- Brain & Cognition
- Administration routes
- Nasal
- Regulatory status
- Not FDA-approved
What it is
A stabilized analog of Selank, marketed for calming anxiety without sedation or dependence. Human evidence is only moderate and mostly borrowed from the parent molecule; BDNF and antidepressant claims are animal or mechanism only. No trials exist on this exact form, so human safety data is essentially absent, with unresolved immune and serotonergic questions. Not an approved drug in the US or Europe, and supply is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(6)
Anxiolytic effects comparable to benzodiazepines without sedation or dependence risk
MediumSmall non-blinded trials of parent Selank, not this analog, matched benzodiazepine anxiolysis; dependence untested.
Rapid elevation of BDNF expression in hippocampus
LowRat studies show parent Selank regulates hippocampal BDNF; no human or NA-amidate data exist.
Immunomodulatory effects — IL-6 modulation, T-helper cell cytokine balance
MediumHuman data limited to lab-cultured cells and one small uncontrolled trial; animal evidence is consistent.
Evidence limits
- Evidence Level
- Very Limited Evidence
Selank (the parent compound) is registered in Russia as an anxiolytic supplied as nonprescription nasal drops and has been studied in several Russian clinical trials for anxiety and cognitive disorders. English-language clinical data is scarce — most published studies are pilot studies or have only abstracts available in English. NA-Selank Amidate specifically has not been tested in clinical trials. The modifications are expected to enhance stability without altering the pharmacological profile significantly, but this has not been clinically validated.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Limited safety data (no formal clinical trials on the NA-Amidate form)
ModeratePotential immunomodulatory effects (IL-6, cytokine balance)
ModeratePossible serotonergic interactions
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.